Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform.

Liang WC, Wang Y, Xiao LJ, Wang YB, Fu WM, Wang WM, Jiang HQ, Qi W, Wan DC, Zhang JF, Waye MM.

RNA Biol. 2014;11(7):845-54. doi: 10.4161/rna.29356. Epub 2014 Jun 12.

2.

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.

Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL.

Gastroenterology. 2008 May;134(5):1521-31. doi: 10.1053/j.gastro.2008.02.015. Epub 2008 Feb 13. Erratum in: Gastroenterology. 2008 Jul;135(1):326.

3.

Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.

Muñoz Ú, Puche JE, Hannivoort R, Lang UE, Cohen-Naftaly M, Friedman SL.

Mol Cancer Res. 2012 Sep;10(9):1216-27. Epub 2012 Aug 2.

4.

The role of KLF6 and its splice variants in cancer therapy.

DiFeo A, Martignetti JA, Narla G.

Drug Resist Updat. 2009 Feb-Apr;12(1-2):1-7. doi: 10.1016/j.drup.2008.11.001. Epub 2008 Dec 18. Review.

PMID:
19097929
5.

Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing.

Vetter D, Cohen-Naftaly M, Villanueva A, Lee YA, Kocabayoglu P, Hannivoort R, Narla G, M Llovet J, Thung SN, Friedman SL.

Hepatology. 2012 Oct;56(4):1361-70. doi: 10.1002/hep.25810. Epub 2012 Aug 27.

6.

A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer.

Chen H, Chen L, Sun L, Zhen H, Li X, Zhang Q.

Gastric Cancer. 2011 Oct;14(4):339-52. doi: 10.1007/s10120-011-0049-x. Epub 2011 May 3.

PMID:
21538018
7.

In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma.

Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, Tarocchi M, Friedman SL.

Oncogene. 2007 Jun 28;26(30):4428-34. Epub 2007 Feb 5.

PMID:
17297474
8.

Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.

Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA.

Cancer Res. 2005 Jul 1;65(13):5761-8.

9.

New candidate tumor-suppressor gene KLF6 and its splice variant KLF6 SV2 counterbalancing expression in primary hepatocarcinoma.

Zhenzhen Z, De'an T, Limin X, Wei Y, Min L.

Hepatogastroenterology. 2012 Mar-Apr;59(114):473-6. doi: 10.5754/hge11283.

PMID:
21940380
10.

Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma.

Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA.

Int J Cancer. 2007 Sep 15;121(6):1390-5.

11.

Biology of Krüppel-like factor 6 transcriptional regulator in cell life and death.

Andreoli V, Gehrau RC, Bocco JL.

IUBMB Life. 2010 Dec;62(12):896-905. doi: 10.1002/iub.396. Review.

12.

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA.

J Clin Invest. 2008 Aug;118(8):2711-21. doi: 10.1172/JCI34780.

13.

Kruppel-like factor 6 suppresses growth and invasion of hepatocellular carcinoma cells in vitro and in vivo.

Wen PH, Wang DY, Zhang JK, Wang ZH, Pan J, Shi XY, Yang H, Zhang SJ, Guo WZ.

Int J Immunopathol Pharmacol. 2016 Dec;29(4):666-675. Epub 2016 Aug 10.

PMID:
27510817
14.

miR-101 acts as a tumor suppressor by targeting Kruppel-like factor 6 in glioblastoma stem cells.

Yao YL, Ma J, Wang P, Xue YX, Li Z, Zhao LN, Li ZQ, Feng TD, Liu YH.

CNS Neurosci Ther. 2015 Jan;21(1):40-51. doi: 10.1111/cns.12321. Epub 2014 Sep 17.

PMID:
25230316
15.

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.

Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, Martignetti JA, Llovet JM, Friedman SL.

J Hepatol. 2007 Apr;46(4):645-54. Epub 2006 Nov 27.

16.

Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene.

Lee UE, Ghiassi-Nejad Z, Paris AJ, Yea S, Narla G, Walsh M, Friedman SL.

FEBS Lett. 2010 Mar 5;584(5):1006-10. doi: 10.1016/j.febslet.2010.01.049. Epub 2010 Jan 30.

17.

KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.

Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, Germain D, Burstein D, Kirschenbaum A, DiFeo A, Foekens JA, Narla G.

Sci Transl Med. 2013 Jan 23;5(169):169ra12. doi: 10.1126/scitranslmed.3004688.

18.

Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function.

Rodríguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA.

PLoS One. 2010 Sep 9;5(9). pii: e12639. doi: 10.1371/journal.pone.0012639.

19.

Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.

Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo EA, Choudhri A, Narla G.

Lung Cancer. 2009 Dec;66(3):292-7. doi: 10.1016/j.lungcan.2009.02.014. Epub 2009 Mar 28.

20.

[Effect of KLF6 and its splice variant KLF6V on proliferation and differentiation of human hepatocellular carcinoma HepG2 cells].

Pan XC, Chen Z, Ji F, Guo ZS, Chen M, Fu JJ.

Zhonghua Gan Zang Bing Za Zhi. 2008 Sep;16(9):683-7. Chinese.

PMID:
18822210

Supplemental Content

Support Center